Iterum Therapeutics(US:ITRM) Globenewswire·2025-10-14 12:30Core Insights - Iterum Therapeutics plc is focused on developing next-generation oral and IV antibiotics to combat infections caused by multi-drug resistant pathogens in both community and hospital settings [1] Group 1: Conference Participation - The company will present two posters at the IDWeek 2025 conference in Atlanta, GA from October 19-22, 2025 [1] - A Learning Lounge session titled "An Overview of Urinary Tract Infection in Adult Women: Focus on Oral Sulopenem" will be conducted on October 21, 2025 [2] - The two posters include: 1. "Risk factors for treatment failure in patients with uncomplicated urinary tract infection" presented by Steven I. Aronin, MD on October 20, 2025 [2] 2. "In vitro activity of sulopenem and comparator agents against U.S. Enterobacterales clinical isolates, SENTRY antimicrobial surveillance program, 2023" presented by Steven I. Aronin, MD on October 21, 2025 [2] Group 2: Product Information - ORLYNVAH™ is a novel oral penem antibiotic specifically designed for treating uncomplicated urinary tract infections (uUTIs) [3] - ORLYNVAH™ is effective against Enterobacterales species that produce extended spectrum beta-lactamases (ESBL) or AmpC-type β-lactamases, which confer resistance to third-generation cephalosporins [3] Group 3: Company Overview - Iterum Therapeutics plc aims to address the global crisis of multi-drug-resistant pathogens with differentiated anti-infectives [4] - The company is advancing sulopenem, a novel penem anti-infective compound, which has shown potent in vitro activity against various resistant bacteria [4] - ORLYNVAH™ has received FDA approval for treating uUTIs caused by Escherichia coli, Klebsiella pneumoniae, or Proteus mirabilis in adult women with limited treatment options and is commercially available in the U.S. [4]